Effect and Safety of Semaglutide 2.4 mg Once-weekly in Subjects With Overweight or Obesity and Type 2 Diabetes
Latest Information Update: 06 Sep 2024
At a glance
- Drugs Semaglutide (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms STEP 2
- Sponsors Novo Nordisk
- 24 Jun 2023 Results of pooled analysis from STEP 1 and STEP 2 presented at the European Association for the Study of the Liver Congress 2023
- 01 Dec 2022 Results assessing the safety and efficacy of a weekly 2.4-mg subcutaneous injection of semaglutide for chronic weight management in STEPS 1-4 studies, published in the American Journal of Managed Care.
- 23 Sep 2022 Results assessing the relationship between body weight loss and glycaemiccontrol in participants with overweight/obesity and T2D receiving semag-lutide pharmacotherapy, esented at the 58th Annual Meeting of the European Association for the Study of Diabetes.